Data from Pharmawand - Curated by EPG Health - Date added 14 March 2018

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of a new analysis showing that Invokana (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk. This exploratory analysis from the CANVAS Program was featured as a late-breaking oral presentation at the American College of Cardiology’s 67th Annual Scientific Session (abstract #407-10) and was simultaneously published in Circulation.

The results showed canagliflozin was associated with a significant reduction in risk of CV death or HHF by 22 percent (HR, 0.78; 95% CI, 0.67 to 0.91), fatal or hospitalized heart failure by 30 percent (HR, 0.70; 95% CI, 0.55 to 0.89); and HHF alone by 33 percent (HR, 0.67; 95% CI, 0.52 to 0.87). The benefit of reduced risk of CV death or HHF was 39 percent (HR, 0.61; 95% CI, 0.46 to 0.80) greater in patients with a prior history of heart failure, compared to the 13 percent (HR, 0.87; 95% CI, 0.72 to 1.06) without heart failure, at baseline. Rates of heart failure varied according to baseline characteristics, such as age, renal function and other disease history characteristics, but effects of canagliflozin on risk of CV death or HHF were mostly comparable across numerous subgroups.

In addition, the data confirmed that proportional effects of canagliflozin compared to placebo were comparable across a broad population of patients with T2D at high CV risk. Specifically, patients from the CANVAS Program included those with and without heart failure at baseline for major adverse CV events (MACE), CV death, myocardial infarction (MI), stroke, all-cause mortality, and serious decline in kidney function. On October 2, 2017, Janssen submitted a supplemental New Drug Application (sNDA) to the FDA seeking a new indication to reduce the risk of MACE based on the CANVAS Program.

The CANVAS Program is the longest, largest and broadest completed CV outcomes program of any sodium glucose cotransporter 2 (SGLT2) inhibitor to date and was the first to assess the efficacy, safety, and durability of canagliflozin in more than 10,000 patients with T2D who had either a prior history of CV disease or at least two CV risk factors. Data from the integrated analysis of the CANVAS and CANVAS-R trials were presented last year in a special symposium at the American Diabetes Association 77th Scientific Sessions on 12 June 2017 in San Diego, CA, and simultaneously published in The New England Journal of Medicine. No new adverse events were observed during this additional analysis beyond those previously reported from the CANVAS Program.

See- "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)"-Karin Rådholm, Gemma Figtree, Vlado Perkovic, Scott D. Solomon, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Terrance D. Barrett, Wayne Shaw, Mehul Desai, David R. Matthews, Bruce Neal. Circulation. 2018;CIRCULATIONAHA.118.034222.Originally published.March 11, 2018.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Type 2 Diabetes

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.



Learn about the complex factors influencing development of obesity.

+ 4 more

Load more

Related Content